Share on StockTwits
 

Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 6.1% during trading on Monday after Wedbush raised their price target on the stock from $449.00 to $493.00, AnalystRatings.NET reports. The stock traded as high as $387.76 and last traded at $373.05, with a volume of 887,813 shares changing hands. The stock had previously closed at $351.56.

A number of other firms have also recently commented on ICPT. Analysts at BMO Capital Markets reiterated an “outperform” rating on shares of Intercept Pharmaceuticals in a research note on Monday, January 13th. Separately, analysts at Citigroup Inc. raised their price target on shares of Intercept Pharmaceuticals to $600.00 in a research note on Monday, January 13th. Finally, analysts at Janney Montgomery Scott raised their price target on shares of Intercept Pharmaceuticals to $300.00 in a research note on Friday, January 10th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $490.83.

The stock’s 50-day moving average is $230.5 and its 200-day moving average is $96.36. The company’s market cap is $7.063 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Thursday, November 14th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $1.14. During the same quarter in the previous year, the company posted ($1.86) earnings per share. Analysts expect that Intercept Pharmaceuticals will post $-3.77 EPS for the current fiscal year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.